Search

Objective To observe the effect of recombinant human acidic fibroblast growth factor combined with fusidic acid cream on patients with deep second-degree burn. Methods From June 2019 to May 2020, 120 patients with deep second-degree burn were selected as the research subjects. All patients were randomly divided into control group 1, control group 2 and observation group, 40 cases in each group. In control group 1, patients were treated with scab ablation combined with recombinant human acidic fibroblast growth factor. In control group 2, patients were treated with scab ablation combined with fusidic acid cream. In the observation group, patients were treated with scab ablation, recombinant human acidic fibroblast growth factor and fusidic acid cream. All patients in 3 groups were treated continuously until wound healing. The interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and transforming growth factor-α1 (TGF-α1) were measured before and 20 days after treatment. The wound healing time was observed, the degree of scar hyperplasia in 3 groups was evaluated by Vancouver Scar Scale (VSS) and the adverse reactions were recorded. Results The level of TNF-α and IL-6 in observation group was lower than that in control group 1 and 2 (P<0.05), the level of IL-2 and IL-10 in observation group was higher than that in control group 1 and 2 (P<0.05), and the level of VEGF, EGF, TIMP-1 and TGF-α1 in observation group was higher than that in control group 1 and 2 (P<0.05). At 10, 15 and 20 days of treatment, the wound healing rate in observation group was higher than that of control group 1 and 2 (P<0.05), and the average wound healing time of observation group was shorter than that of control group 1 and 2 (P<0.05). The scores of vascular distribution, color, thickness and softness of scar in observation group was lower than those of control group 1 and 2 (P<0.05). No obvious adverse reactions occurred in 3 groups. Conclusion Application of recombinant human acidic fibroblast growth factor combined with fusidic acid cream in the treatment of deep second-degree burn can reduce the level of pro-inflammatory factors of TNF-α and IL-6, increase the level of anti-inflammatory factors of IL-2 and IL-10, inhibit inflammation, increase the level of VEGF, EGF, TIMP-1 and TGF-α1, improve wound healing rate and reduce scar hyperplasia. The safety was high. [ABSTRACT FROM AUTHOR]

Objective: To analyze the clinical efficacy of compound honeysuckle decoction hot and humid joint fusidic acid cream in the treatment of targeted drugs-induced rash. Methods: 80 cases of patients with targeted drugs-induced rash admitted in our hospitalfrom August 2014 to August 2016 were selected and divided into two groups with 40 cases in each group according to the drawing method. The control group was treated by fusidic acid cream, while the observation group was treated by compound honeysuckle decoction hot and humid joint fusidic acid cream, the changes of symptom score, quality of life after treatment, clinical efficacy and incidence of adverse reactions were compared between two groups. Results: After treatment, the symptoms score of observation group ((6.87± 1.25) points) was lower than that of the control group ((10.29± 2.74) points)(P＜0.05), the quality of life score ((3.15± 0.57)points) of observation group was lower than that of the control group ((6.42± 1.20) points)(P＜0.05). The effective rate of observation group(95.00％) was higher than that of the control group(77.50％)(P＜0.05), no statistical difference was found in the incidence of adverse reactions was observed between two groups (P＞0.05). Conclusion: Compound honeysuckle decoction hot and humid joint fusidic acid cream was effective in the treatment of targeted drugs-induced rash, it could effectively relieve the clinical symptoms, improve the quality of life. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the efficacy of ceftizoxime sodium for injection combined with fusidic acid cream in treatment of sequela ulcer of leprosy. METHODS: 64 patients with sequela ulcer of leprosy admitted into Leprosy Control and Prevention Center of Xiaogan from Nov. 2015 to Jun. 2017 were selected and divided into observation group and control group via random number table, with 32 cases in each. The control group was treated with ceftizoxime sodium for injection, while the observation group was given fusidic acid cream for external use based on the control group. Differences in clinical efficacy, quality of life (QOL) scores and incidences of relapse between two groups were compared. RESULTS: The total effective rate of observation group (93.75%, 30/32) was significantly higher than that of the control group (75.00%, 24/32), with statistically significant difference (P < 0.05); at the 8th week after treatment, the QOL score of observation group was significantly higher than that of the control group, with statistically significant differences (P < 0.05); at the 8th week after treatment, the incidence of relapse of observation group (0, 0/32) was significantly lower than that of the control group (21.88%, 7/32), with statistically significant difference (P < 0.05). CONCLUSIONS: The efficacy of ceftizoxime sodium for injection combined with fusidic acid cream in treatment of sequela ulcer of leprosy is remarkable, which can improve patients' ulcer, promote quality of life and reduce the incidence of relapse. [ABSTRACT FROM AUTHOR]